MetaVia (MTVA) Stock Price, News & Analysis

Company Overview

MetaVia, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide-based medicines for obesity, metabolic disorders and related diseases. The company’s programs are designed to address conditions such as obesity-associated liver disease and other complications of metabolic dysfunction.

MetaVia’s lead product candidate is pemvidutide, an investigational once-weekly dual GLP-1 and glucagon receptor agonist. The company is evaluating pemvidutide for chronic weight management and metabolic dysfunction-associated steatohepatitis, now commonly referred to as metabolic dysfunction-associated steatohepatitis or MASH. The treatment is intended to combine weight-loss effects with potential benefits for liver health and broader metabolic function.

The company was formerly known as Altimmune, Inc. and changed its corporate name to MetaVia. Based in the United States, MetaVia conducts clinical development activities intended to support potential commercialization in major global healthcare markets. Vipin K. Garg has served as the company’s president and chief executive officer.

Key Stats

• Today's Range: $1.51 to $1.65
• 50-Day Range: $1.42 to $1.84
• 52-Week Range: $0.97 to $14.85
• Volume: 61,412 shs
• Average Volume: 85,225 shs
• Market Capitalization: $7.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Hold

MetaVia Stock Analysis - MarketRank™

MetaVia scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

MetaVia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

MetaVia has a consensus price target of $20.00, representing about 1,198.7% upside from its current price of $1.54.

Amount of Analyst Coverage

MetaVia has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MetaVia are expected to decrease in the coming year, from ($2.79) to ($3.02) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MetaVia is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MetaVia is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MetaVia has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.57% of the float of MetaVia has been sold short.

Short Interest Ratio / Days to Cover

MetaVia has a short interest ratio ("days to cover") of 1.49, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MetaVia has recently decreased by 12.99%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MetaVia does not currently pay a dividend.

Dividend Growth

MetaVia does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for MetaVia this week, compared to 3 articles on an average week.

MarketBeat Follows

2 people have added MetaVia to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MetaVia insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.60% of the stock of MetaVia is held by insiders.

Percentage Held by Institutions

1.37% of the stock of MetaVia is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MTVA
• Previous Symbol: NASDAQ:NRBO
• CIK: 1638287
• Web: www.metaviatx.com
• Phone: 857-702-9600
• Fax: 734-293-0444
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Price Target for MetaVia: $20.00
• High Price Target: $20.00
• Low Price Target: $20.00
• Potential Upside/Downside: +1,198.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.97 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -209.67%
• Return on Assets: -107.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.06
• Quick Ratio: 2.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.31 per share
• Price / Book: 0.67

Miscellaneous

• Outstanding Shares: 5,160,000
• Free Float: 5,133,000
• Market Cap: $7.95 million
• Optionable: N/A
• Beta: 0.96